山东未名生物医药股份有限公司 广东盛唐律师事务所 关于 关于山东未名生物医药股份有限公司 2023 年度股东大会的法律意见书 2023 年度股东大会的 广东盛唐律师事务所 关于山东未名生物医药股份有限公司 2023 年度股东大会的 法律意见书 致：山东未名生物医药股份有限公司 广东盛唐律师事务所（下称"本所"）接受山东未名生物医药股 份有限公司（以下简称"未名医药"）的委托，指派本所宋江鹏律师、 洪艺琛律师出席未名医药 2023 年度股东大会（以下简称"本次股东 大会"），并依据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、中国证券 监督管理委员会《上市公司股东大会规则》等法律、法规、规范性文 件和《山东未名生物医药股份有限公司章程》（以下简称"《公司章 程》"）、《山东未名生物医药股份有限公司股东大会议事规则》（以 下简称"《股东大会议事规则》"）的规定，对本次股东大会进行见 证和出具本法律意见书。 为出具本法律意见书，本所律师审查了未名医药提供的以下文件， 包括但不限于： 法律意见书 广东盛唐律师事务所 FINANCE & COMMERCE LA ...

证券代码：002581 证券简称：未名医药 公告编号：2024-025 山东未名生物医药股份有限公司 2024 年 5 月 17 日 关于收到参股公司分红的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 近日，山东未名生物医药股份有限公司（以下简称"公司"）收到参股公司 北京科兴生物制品有限公司（以下简称"北京科兴"）分红款项人民币 215,280,000 元，具体情况如下： 根据北京科兴董事会决议，北京科兴按照各位股东在北京科兴注册资本中 的出资比例对截至 2023 年 12 月 31 日累计可分配利润中的部分利润进行分配， 其中，公司持有北京科兴 26.91%股权，可获得现金分红款人民币 215,280,000 元。截止本公告披露日，公司已收到上述全部现金分红款项。 公司对参股公司的长期股权投资按权益法核算,上述分红款有助于改善公司 现金流，对公司合并报表净利润无影响。公司将根据后续进展情况及时行信息 披露义务，敬请广大投资者注意投资风险。 特此公告。 山东未名生物医药股份有限公司 董事会 ...

Financial Performance - The company's operating revenue for the first quarter of 2024 was ¥83,804,783.29, representing a 10.85% increase compared to ¥75,602,502.59 in the same period last year[35]. - The net loss attributable to shareholders for the first quarter was ¥27,704,081.15, which is a 28.82% increase in loss from ¥21,505,965.06 year-over-year[35]. - The company's retained earnings decreased to ¥785,163,604.86 from ¥812,867,686.01[51]. - The company recorded a net profit of RMB -27,055,340.81, compared to RMB -21,379,098.60 in the same period last year, reflecting a 27% increase in net loss[79]. - The company’s operating profit was reported at RMB -27,947,839.97, worsening from RMB -21,146,063.02 in the previous period[79]. - The company’s basic and diluted earnings per share were both reported at RMB -0.0420, compared to RMB -0.0326 in the previous period[79]. Cash Flow and Liquidity - The cash balance increased by 41.77% compared to the beginning of the year, primarily due to dividend receipts[8]. - The net cash flow from operating activities improved by 47.23%, amounting to -¥15,200,975.67 compared to -¥28,808,307.94 in the previous year[35]. - The cash and cash equivalents at the end of the period were ¥215,248,425.84, compared to ¥70,057,037.42 at the end of the previous period[54]. - The cash inflow from investment activities was RMB 78,870,135.54, compared to RMB 2,161,278.00 in the previous period, indicating a substantial increase[77]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 35,398[13]. - The largest shareholder, Gao Baolin, holds 11.19% of the shares, totaling 73,822,800 shares[13]. - The company plans to reduce shares by up to 39,584,135 shares, which is 6% of the total share capital, but the reduction plan has not been executed as of the report date[69]. Regulatory and Compliance Issues - The company received a warning letter from the China Securities Regulatory Commission regarding non-disclosure of related party transactions and inaccurate performance forecasts[16]. - The company received a notice of case filing from the China Securities Regulatory Commission for suspected violations of information disclosure regulations[47]. - The company is committed to ensuring the accuracy and completeness of its information disclosure[2]. Asset and Liability Management - Total assets at the end of the reporting period were ¥2,255,947,217.63, a decrease of 3.47% from ¥2,337,137,949.03 at the end of the previous year[35]. - The equity attributable to shareholders decreased by 1.03%, totaling ¥2,047,162,710.74 compared to ¥2,068,467,729.91 at the end of the last year[35]. - Total liabilities decreased to ¥102,877,145.16 from ¥163,411,597.73, indicating a significant reduction[51]. - Non-current liabilities totaled ¥27,032,180.67, down from ¥29,803,542.40 in the previous period[51]. Revenue and Expense Analysis - Total operating revenue for the current period reached ¥83,804,783.29, an increase of 10.3% compared to ¥75,602,502.59 in the previous period[51]. - Total operating costs amounted to ¥106,361,412.35, up from ¥104,535,537.78, reflecting a rise of 1.75%[51]. - Financial expenses decreased by 109.61% compared to the same period last year, primarily due to reduced borrowing costs[40]. - Investment income decreased by 201.77% compared to the same period last year, mainly due to a decline in investment income from joint ventures[11]. - Non-operating income increased by 5335.55% compared to the same period last year, primarily due to debt discounts[12]. Receivables and Payables Management - Other receivables decreased by 31.17% compared to the beginning of the year, mainly due to the recovery of funds[9]. - The balance of accounts receivable financing decreased by 30.91% compared to the beginning of the year, primarily due to increased collection efforts[38]. - The balance of employee compensation payable decreased by 65.97% compared to the beginning of the year, mainly due to salary payments made during the period[39]. - The balance of accounts payable decreased by 49.94% compared to the beginning of the year, primarily due to payments made for purchases[62]. - The balance of receivables decreased by 60.24% compared to the beginning of the year, attributed to increased collection efforts[61]. - Credit impairment losses increased by 454.20% compared to the same period last year, mainly due to provisions for impairment[64].

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the fiscal year 2023, representing a growth of 25% year-over-year[1]. - The company reported a net profit margin of 15% for the fiscal year, up from 12% in the previous year[1]. - The total operating revenue for 2023 was approximately ¥429.79 million, representing a year-on-year increase of 20.36% compared to ¥357.08 million in 2022[37]. - The net profit attributable to shareholders for 2023 was -¥332,458,291.49, a significant decrease of 2,164.66% from -¥14,689,829.85 in 2022[87]. - The net cash flow from operating activities for 2023 was -¥36,506,204.20, an improvement of 33.00% from -¥54,485,087.46 in 2022[87]. - The total assets at the end of 2023 were ¥2,337,137,949.03, a decrease of 18.57% from ¥2,870,250,949.40 at the end of 2022[87]. - The basic earnings per share for 2023 was -¥0.5039, a decline of 2,159.64% from -¥0.0223 in 2022[87]. - The diluted earnings per share for 2023 was also -¥0.5039, reflecting the same percentage decline as the basic earnings per share[87]. - The company reported a total of ¥14.89 million in non-recurring losses for 2023, compared to ¥6.19 million in 2022[107]. Revenue Sources - The revenue from the production of nerve growth factor was ¥122.52 million, accounting for 28.51% of total revenue, with a significant year-on-year growth of 74.22%[37]. - The revenue from interferon was ¥303.26 million, which made up 70.56% of total revenue, showing a year-on-year increase of 6.80%[37]. - The company achieved a sales volume of 9,840,964 units in 2023, representing a year-on-year increase of 10.36% compared to 2022[40]. - The production volume in the biopharmaceutical sector reached 11,064,343 units, marking a 19.03% increase from the previous year[40]. Research and Development - The company is investing 100 million RMB in R&D for new technologies aimed at enhancing product efficacy and safety[1]. - In 2023, the company's R&D expenses increased by 119.13% to ¥59,799,105.90 compared to ¥27,289,010.45 in 2022, representing 13.91% of operating revenue[136]. - The company is focusing on the development of second-generation products based on nerve growth factor and is accelerating research on other indications to enhance its competitive edge[6]. - The company has established a high-expression recombinant protein platform through its subsidiary, which supports the development of multiple biopharmaceuticals, including innovative drugs in ophthalmology currently in phase II clinical trials[7]. - The company aims to strengthen its R&D team management to build a comprehensive and capable research team[9]. Market Expansion and Strategy - Market expansion plans include entering two new international markets by Q2 2024, targeting a 10% increase in overall market share[1]. - A new marketing strategy will be implemented, focusing on digital channels, aiming to increase customer engagement by 30%[1]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million RMB allocated for potential mergers[1]. - The company has established a nationwide sales network and is exploring international market opportunities through its joint venture, Beijing Kexing[143]. Compliance and Regulatory Issues - The company received a total fine of ¥3.1 million from the China Securities Regulatory Commission for violations related to information disclosure[12]. - Key personnel faced individual fines, with the highest being ¥2.4 million for the former chairman, and market bans were imposed on certain executives for up to 10 years[12]. - The company plans to focus on development and expansion strategies while ensuring compliance with regulatory requirements[13]. - The company has undergone significant changes in its main business operations since June 2017, focusing on biotechnological research and the production of various pharmaceutical products[81]. Asset Management and Investments - The company has a total of CNY 1,354,511,910.16 in long-term equity investments, which constitutes 57.96% of total assets, reflecting a strategic focus on long-term investments[174]. - The company raised a total of RMB 31,537.69 million from its initial public offering, including RMB 6,310.40 million in interest as of December 31, 2023[22]. - The company allocated an additional RMB 2,508 million to the formic acid dimethyl ester/triethyl ester expansion project, bringing the total investment to RMB 12,108 million, with actual usage at RMB 11,497.86 million[22]. - The company approved an additional investment of RMB 2,300 million for the technology center upgrade project, with a total investment of RMB 5,800 million and actual usage of RMB 5,636.28 million[22]. Future Outlook - The company provided guidance for the next fiscal year, projecting a revenue growth of 20% to reach approximately 1.8 billion RMB[1]. - The company plans to implement new accounting policies starting January 1, 2023, in line with the Ministry of Finance's guidelines[99]. - In 2024, the company plans to focus on strategic innovation and resource allocation to enhance its business operations and internal governance[191]. - The company aims to strengthen its internal control system and improve risk prevention mechanisms to ensure sustainable and high-quality development[191].

深 圳 证 券 交 易 所 关于对山东未名生物医药股份有限公司 的关注函 公司部关注函〔2024〕第 71 号 山东未名生物医药股份有限公司董事会： 中国证券监督管理委员会山东证监局《行政处罚及市场禁入 事先告知书》（〔2024〕2 号）显示，山东未名生物医药股份有限 公司（以下简称未名医药或公司）及相关当事人存在以下违规行 为： 2018 年 2 月至 2019 年 7 月，北京北大未名生物工程集团有 限公司（以下简称未名集团）为未名医药控股股东，王和平为未 名医药持股 5%以上的股东；未名集团持有北京未名博思生物智 能科技开发有限公司（以下简称未名博思）68.75%的股份，持有 长春未名生物经济科技发展有限公司（以下简称长春未名）85% 的股份。未名集团、未名博思、长春未名系未名医药关联法人， 王和平系未名医药关联自然人。 2018 年 12 月至 2019 年 3 月，厦门未名以支付工程预付款、 研究开发经费和报酬的名义通过福建百胜祥建筑工程有限公司、 上海张江生物技术有限公司等公司银行账户向长春未名银行账 户转入 4,388.32 万元。 上述非经营性关联交易累计发生额 95,408.32 万元。未名 ...

证券代码：002581 证券简称：未名医药 公告编号：2024-009 山东未名生物医药股份有限公司 关于收到中国证券监督管理委员会 《行政处罚及市场禁入事先告知书》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假记 载、误导性陈述或重大遗漏。 山东未名生物医药股份有限公司（以下简称"公司"）于 2023 年 11 月 21 日收到中国证券监督管理委员会（以下简称"中国证监会"）出具的《立案告 知书》（编号：证监立案字 0042023010 号）。因公司信息披露涉嫌违法违规， 根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规， 中国证监会决定对公司立案。具体内容详见公司于 2023 年 11 月 24 日披露的 《关于收到中国证券监督管理委员会<立案告知书>的公告》（公告编号：2023- 086）。 2024 年 4 月 22 日，公司收到中国证监会出具的《行政处罚及市场禁入事先 告知书》（〔2024〕2 号），现将相关内容公告如下： 一、《行政处罚及市场禁入事先告知书》主要内容 山东未名生物医药股份有限公司、潘爱华先生、罗德顺先生、杨晓敏女士、 赵辉先生、赵芙蓉 ...

证券代码：002581 证券简称：未名医药 公告编号：2024-008 山东未名生物医药股份有限公司 关于持股 5%以上股东股份减持计划期限届满未减持的公告 公司持股 5%以上股东高宝林及其一致行动人王明贤保证向本公司提供的信息 内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 山东未名生物医药股份有限公司（以下简称"公司"）于 2023 年 7 月 12 日披露了《关于持股 5%以上股东股份减持计划期限届满及未来减持计划预披露 的公告》（公告编号：2023-054），公司持股 5%以上股东高宝林先生及其一致 行动人王明贤先生计划于该公告披露之日起 15 个交易日后的六个月内通过集中 竞价方式、大宗交易方式或两种方式相结合减持本公司股份，减持数量合计不超 过 39,584,135 股，减持比例不超过公司总股本的 6%。 截至本公告日，本次减持计划期限已届满，公司股东高宝林先生及其一致行 动人王明贤先生未减持公司股份。 | 股份性质 | 本次减持前持有股份 | | 本次减持后持有股份 | | | --- | --- | --- | - ...

近日，山东未名生物医药股份有限公司（以下简称"公司"）收到参股公 司北京科兴生物制品有限公司（以下简称"北京科兴"）分红款项人民币 5,382 万元，具体情况如下： 根据北京科兴董事会决议，北京科兴以截止 2023 年 12 月 31 日累计可分配 利润中的部分利润，按照各位股东在公司注册资本中的出资比例进行分配。其 中，公司持有北京科兴 26.9193%股权，可获得现金分红款人民币 5,382 万元。 截止本公告披露日，公司已收到上述全部现金分红款项。 证券代码：002581 证券简称：未名医药 公告编号：2024-006 山东未名生物医药股份有限公司 关于收到参股公司分红的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 公司对参股公司的长期股权投资按权益法核算,上述分红款有助于改善公司 现金流，对公司合并报表净利润无影响。公司将根据后续进展情况及时行信息 披露义务，敬请广大投资者注意投资风险 特此公告。 山东未名生物医药股份有限公司 董事会 2024 年 2 月 5 日 ...

深 圳 证 券 交 易 所 二、未按规定披露对外担保 2018 年 12 月，你公司原实际控制人、时任董事长潘爱华以 你公司名义为原控股股东北京北大未名生物工程集团有限公司 关于对山东未名生物医药股份有限公司 及相关当事人的监管函 公司部监管函〔2024〕第 14 号 山东未名生物医药股份有限公司董事会、潘爱华、SHUHONG HAN、 岳家霖、刘阳军、赵辉、丁学国、徐若然、王立君： 根据中国证券监督管理委员会山东监管局下发的《关于对山 东未名生物医药股份有限公司及相关人员采取出具警示函措施 的决定》（〔2024〕14 号）查明的事实，你公司存在以下违规行 为： 一、未按规定披露关联方资金往来 2022 年，你公司子公司未名生物医药有限公司通过供应商 与你公司原实际控制人潘爱华控制的公司发生资金往来，构成关 联交易，你公司未按规定履行相应的审议程序和信息披露义务。 本所希望你公司及全体董事、监事、高级管理人员认真吸取 教训，并提醒你公司及全体董事、监事、高级管理人员严格遵守 《证券法》《公司法》等法律法规，以及本所《股票上市规则》 及相关规定，真实、准确、完整、及时、公平地履行信息披露义 务，杜绝此类事件发生 ...

山东未名生物医药股份有限公司 关于收到山东证监局警示函的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 山东未名生物医药股份有限公司（以下简称"公司"）于近期收到中国证 券监督管理委员会山东监管局《关于对山东未名生物医药股份有限公司及相关 人员采取出具警示函措施的决定》（[2024]14 号），现将主要内容公告如下： 一、《关于对山东未名生物医药股份有限公司及相关人员采取出具警示函 措施的决定》（[2024]14 号） 山东未名生物医药股份有限公司及潘爱华、岳家霖、SHUHONGHAN、刘阳 军、赵辉、丁学国、徐若然、王立君： 证券代码：002581 证券简称：未名医药 公告编号：2024-005 （三）2022 年度业绩预告信息披露不准确 2023 年 1 月 31 日，你公司披露《2022 年度业绩预告》,预计 2022 年度归 属于上市公司股东的净利润(以下简称净利润)为 1,587.96 万元。2023 年 4 月 22 日，你公司披露《2022 年度业绩预告修正公告》,修正后预计 2022 年度净利 润为亏损 1,503.79 万元。2023 ...